Cyprotex Share Discussion Threads

[worrier] 23/9/2010 21:27

Have been into the markets just prior to the dotcom boom. Made a fortune should have retired- then lost 90% of the gains so take a pragmatic view now and tend to look for value and hold long. Easily worried since then . My average price with CRX is errrrr
a touch over 13p ! Got CRX wrong a few years ago.

Worrier

[husbod] 23/9/2010 10:27

Glad you'r not worried worrier. Should we worry if you become worried or is that just your natural state. Maybe if you become REALLY worried then we should start to worry?

Funny word worry when you really start to look at it.

[worrier] 23/9/2010 09:32

just lack of news on progressing developments since the recent corporate activity. These guys are top notch scientists, who might be well advised to improve the company PR,to raise the company profile, but no cause for alarm imho
Not worried

[cotton4] 23/9/2010 09:25

Reckon some are taking profits, awaiting further news. Does anyone know if a broker note has been issued yet?

[husbod] 23/9/2010 08:46

Why the drift down - lack of news or ......

[buywell2] 23/9/2010 08:26

Note now Cyprotex has 500 clients , this is higher than that mentioned in the 'proactive investor's' post.

PLUS ALSO NOW

''THE WORLD'S LARGEST CONTRACT RESEARCH ORGANISATION specialising in ADME Tox''

From the latest TB Alliance RNS

''Cyprotex are the world's largest contract research organisation specialising in
preclinical ADME Tox. The company was established in 1999 and works with over 500 customers worldwide, ranging from small biotech organizations to large
pharmaceutical companies. Cyprotex support a wide range of in vitro and in
silico ADME Tox and PK services, extending from early drug discovery through to
IND submission.
For more information on Cyprotex please visit www.cyprotex.com.''

[moosh2] 22/9/2010 19:29

might as well wait for the daily slow stochastic to go oversold. might happen tomoz or day after. it's when bargains usually appear and when it's probably best to hit the share with buying volume. hopefully it will bounce off a 26 day EMA at the same time too. let's see.

[buywell2] 22/9/2010 09:27

....... Molecular Diagnostics is one of the FASTEST growth sectors around .........

Molecular diagnostics (MDx) is becoming increasingly entwined with the development of pharmaceutical drugs. Initially, it was used in clinical settings to aid diagnosis, prognosis, and optimal treatment, but now, backed by regulatory authorities, it is becoming important in the development and commercialization of new and existing therapies. As a result, the MDx industry, already a multibillion-dollar market, will continue to expand at a significant pace.


Research Highlights

• Globally, In Vitro Diagnostics market will cross US$ 60 Billion by 2014
• Point of Care Testing dominates the In Vitro Diagnostics market with more than 30% market share in 2009
• Molecular Diagnostics is the fastest growing segment in the In Vitro Diagnostics market, its market share will reach approximately 18% by 2014
• In 2009 Roche, Siemens and Abbott Diagnostics together controls 42% market share in In Vitro Diagnostics, Roche controls the highest market share
• After Point of Care Testing, Immunoassay is the second largest market with a market of more than US$ 7 Billion in 2009
• Europe with more than US$ 10 Billion is the second largest In Vitro Diagnostics Market in 2009
• 51 Mergers & Acquisitions taken place in 2008 compared to 84 deals in 2007
• 18 In-Licensing deals were announced in 2008 compared to 27 in 2007
• By 2009 there were 12 countries with more than 10 Million people aged 60 or over
• Third Wave Technologies (TWT) was acquired by Hologic to grow its existing women's health and diagnostics business was the best deal in 2008
• In 2009, Beckman Coulter acquired the diagnostic systems part of Olympus's life sciences to broaden its clinical chemistry offering, especially in the ultra-high throughput setting.

[buywell2] 20/9/2010 08:54

In 2007 there was a trading update early October

In 2008 it was in early November

In 2009 it was Nov 20th

I hopw we get one as in 2007 , so that investors are informed as early as possible what impact the Apredica/Cellumen purchase will make on this years profits

[spekky] 16/9/2010 08:05

You may be right.

[cotton4] 16/9/2010 07:31

Cyprotex's in vitro and in silico ADME Tox technologies will be utilised to help accelerate TB drug discovery. Cyprotex's unique Cloe® Screen platform use state-of-the-art robotics and a sophisticated customised information management system which dramatically reduce the cost and time in generating data while ensuring high reproducibility.

Spekky - I read from this paragraph that there would be a cost to the TB Alliance, but it would save them money.

[cotton4] 16/9/2010 07:27

It just says that the Allaince is non-profit making. That's not to say that there will nothing financially for CRX. Given the current potential expansion with the recent acquisitions, I would be surprised that they would use scarce resources in this area without some financial reward. Especially at this time.

[spekky] 16/9/2010 07:12

When I saw it the other day I thought it should have been rns'd,great publicity in helping solve a worldwide problem (even if it won't add to the bottom line).Its important to be involved in projects like this.

[cotton4] 16/9/2010 07:09

RNS was on website a few days back. Must have felt it was worth an RNS.

[moosh2] 15/9/2010 18:14

seem to be v buy heavy. surely we have to move up soon!!

[buywell2] 15/9/2010 09:58

Apredica/Cellumen purchase puts Cyprotex into the Molecular Diagnostic Ballpark



Cell-Based Assays

Cell-Based Assays
Optimising methods and integrating new platforms for drug discovery, development and toxicity testing

Date: 20 - 22nd September, 2010

Location: London, UK

Presenting: Katya Tsaioun, Chief Scientific Officer

[buywell2] 15/9/2010 09:32

Interesting stakeholders in TB Alliance

Molecular Diagnostic Market Heating Up
K. K. Jain, M.D. Growth Being Driven by Sequencing Advances and the Personalized Medicine quest.

The scope of the molecular diagnostic market is much wider than usually realized, which tends to skew market estimates. Many reports that attempt to estimate the size of the molecular diagnostic market fall short because new technologies, including biomarkers, copy number variation, and DNA sequencing, which are integral to the category, are overlooked.

The worldwide molecular diagnostic market, including peripheral technologies, in vitro and in vivo diagnostics, and molecular imaging, was worth $9 billion in 2009. It is estimated that the market will expand to $15.5 billion in 2014 and $42.5 billion in 2019. New technologies have been responsible for 15 years of steady growth in the sector.

Apart from the market value in dollars, another growth indicator has been an increase in the number of major players involved in the sector. The number of companies actively involved in developing molecular diagnostics increased from less than 100 in 1995 to over 500 in 2010.

Overlap in several molecular diagnostic technologies makes it difficult to divide the market more precisely. The complex relationship between molecular diagnostics and other technologies is shown in the Figure.

DNA sequencing, which is currently used mostly in research with emerging applications in drug discovery and molecular diagnostics, is one of the most promising contributors to growth in the molecular diagnostic sector. DNA sequencing and molecular diagnostics are intricately linked to the concept of personalized medicine.

Genomic medicine, a component of personalized medicine, suggests that the sequencing of the human genome will enable healthcare to enter an era in which an individual patient's genome will help determine the optimal approach to care, whether it is preventive, diagnostic, or therapeutic. Personalized genome sequencing, as a result, will likely become an integral part of personalized medicine in the near future.

DNA Sequencing

The value of the DNA sequencing market in 2009, including reagents and instruments, was $700 million worldwide, with U.S. sales contributing over $500 million of that. The market is estimated to expand to $900 million by 2014 and $1.8 billion by 2019.

Sequencing is still quite expensive, but initiatives to bring the cost of sequencing one's genome down to $1,000 are under way and should be realized soon. Right now, however, the greatest need is for simple-to-operate, portable, and affordable small sequencers that can be integrated into point-of-care diagnostics, as well as used for research in smaller laboratories.

The use of small sequencers is likely to expand considerably, particularly with the increasing acceptance of personalized medicine. There are over 300,000 scientists working in smaller peripheral laboratories worldwide, and as a result, there is a market potential for at least 50,000 small sequencers over the next five years.

Companies that develop large sequencing machines are aware of the demand for small sequencers and are advancing next-generation products that are less expensive and more suitable for smaller laboratories, although, cost and operational expertise remain limiting factors for broad usage.

[buywell2] 14/9/2010 08:31

Molecular Diagnostics has emerged as the fastest growing segment in vitro diagnostics industry
Bharatbook added a new report on "Global Molecular Diagnostics Market: Opportunities & Future Forecast" which gives the challenges and growth of Molecular Diagnostics Market.

FOR IMMEDIATE RELEASE

PRLog (Press Release) – Aug 27, 2010 – Global Molecular Diagnostics Market: Opportunities & Future Forecast

This research report provides the global molecular diagnostics industry past present and future scenario. The specific clinical segments like Infectious Disease Testing Market, ID/forensics Market, Tissue Typing Market, Oncology Market, Food Testing Market, Genetic Testing Market and Pharmacogenomics Market past, present and future scenario has been analyzed in this report. The report provides separate comprehensive past, present and future forecast of molecular diagnostics market on country level as well. Countries covered in the report are: US, Europe and India. ( ... )

Market Overview

Based on its exceptional ability to accurately detect the primary cause of disease, molecular diagnostics has emerged as the fastest growing segment of the in vitro diagnostics (IVD) industry. Growing with a CAGR of 19 percent global molecular diagnostics market is expected to reach US$ 7 Billion by 2011. The infectious disease was having the biggest market share of 70 percent but gradually its share will decline to 50 percent. The future growth is expected to come from Oncology Testing, Genetic Testing and Pharmacogenomics Testing.

Geographically, the US and European markets are the most advanced in terms of adoption of molecular testing and make up the majority of the existing market. However Indian molecular diagnostics market is also catching up fast and future growth is expected from these markets when US and European market will mature. Key player wise molecular diagnostics market is dominated by big companies such as Roche Diagnostics, Gen-Probe, Siemens Healthcare Diagnostics Inc. and Abbott Laboratories which are active in every segment of the clinical diagnostics market. They have broader product portfolios, which can address the needs of any kind of clinical laboratories. However, their leadership is likely to be challenged by the emergence of a new breed of players who target growth areas such as oncology and pharmacogenomics.

For more information kindly visit : ...

Related Reports

Molecular Diagnostics - Technologies, Markets and Companies
...

The World Market for Molecular Diagnostics

[cotton4] 13/9/2010 14:08

News

September 13, 2010 - Cyprotex and TB Alliance form collaboration to aid the struggle against global tuberculosis (TB)

[moosh2] 10/9/2010 17:58

errrrm, when a share is in proper uptrend, you really don't have to keep posting stuff on a BB to keep the share price afloat lol. you might get accused of ramping!

[buywell2] 10/9/2010 09:41

The Cellumen acquisition puts Cyprotex into the 'Molecular Diagnostics' arena, a place where GREAT prospects await.



A place that some may recall that Tepnel Life Sciences used to live before it was gobbled up by Gen-Probe

my second choice stock Source BioScience ( SBS ) also lives in 'Molecular Diagnostics Avenue ' and has been attracting attention from the big boys




This report is well worth a read ...



Note Gen-Probe gets a mention , and note the growth rate predictions for molecular diagnostics

This means
1. No precious time is lost for the patient AND they get a drug that will work on them

2. Cash strapped Health Depts , like the NHS or Medicare , save taxpayers money by not using drugs that sometimes cost around 20,000 pounds per patient or more ..... and then finding it did not work on them because of their genetic makeup.


Cellumen, MTPC to Develop Biomarker Panels for Early-Stage Drug Tox Screens
August 22, 2008

By Charlotte LoBuono

Cellumen this week announced an agreement with Japan's Mitsubishi Tanabe Pharma Corporation to develop biomarker panels to identify toxicity early in the drug-development process.

This agreement marks Cellumen's first play in the Asian market, but a company official said "there will be more to follow." He did not elaborate.

MTPC and Cellumen are testing new classes of cellular functional biomarkers to build new biomarker panels for Cellumen's CellCiphr product line, said Cellumen CEO Lansing Taylor. "We started with existing panels, and are building a range of new ones," he said.

Taylor declined to elaborate, but said that Cellumen will be selling all the panels, reagents, and biomarkers that are developed under the agreement.

The MTPC collaboration spun out of an initial project that the company engaged with Cellumen, said Don Taylor, Cellumen's senior director of marketing and corporate development.

Taylor said Cellumen chose to work with MTPC because it is "one of the leaders in the pharmaceutical industry in the Asian market."

He added that the firm is "progressive" in its drug discovery and drug development. "They are interested in exploring a wide range of biomarkers," and are approaching this collaboration from a very scientific standpoint, said Lansing Taylor.

Cellumen is open to future collaborations with MTPC. "They obviously believe in our cellular systems biology approach, which really underpins [Cellumen's] CellCiphr profiling service," Don Taylor said. He added that MTPC also recognizes the value of Cellumen's existing profiling panels by collaborating with Cellumen in discovery toxicology.


--------------------------------------------------------------------------------
"We started with existing panels, and are building a range of new ones."

--------------------------------------------------------------------------------


Taylor declined to give a timeline for Cellumen's current collaboration with MTPC, but said that the project "is currently underway."

In late July, Cellumen announced that it was spinning out its personalized medicine unit into a separate entity called Cernostics Pathology (see CBA News, 7/18/08). The new company will provide digital imaging pathology and tissue-based diagnostic products and services.

Cernostics is in the process of getting more funding, said Taylor. He also mentioned that Cernostics' breast cancer patient stratification project with the Mayo Clinic is "moving along well." In terms of the amount of money sought by Cernostics, "I would say that some time in September, we will have decided on our detailed steps," he said.

Cellumen itself is stronger because its "core focus is on discovery toxicology, and we are serving this high-growth, currently underserved market," Taylor said.

In a separate deal announced earlier last month, Cellumen said it would use its CellCiphr technology to profile blinded samples of 50 compounds, including failed and marketed drugs, for the National Center for Toxicological Research, a research center of the US Food and Drug Administration (see CBA News, 7/7/08).

The NCTR "is a strong collaborator and very responsive to us. We are completely on schedule," said Taylor.

In the fall, Cellumen will have additional announcements, concerning other big pharma customers that are coming on board, said Taylor. When asked if Cellumen plans to establish a footprint in the European market, Taylor said, "We are about to."

Cellumen is also launching a new CellCiphr panel this fall that comprises H2C9 mouse cardiomyoblasts, said Taylor.



Not suprising ..... because for example , using MD means that many different types of cancer patients can be tested to ensure the efficacy of cancer drugs before the drugs are used.

[buywell2] 09/9/2010 08:40

Looked into predictive businesses ..... seems some are doing very well in the states

[spekky] 08/9/2010 10:50

sparty

I have just been recapping some posts that I missed whilst in France recently.I've got to say the Proactive article you linked to is one of the best I've seen on CRX and make no apology for posting the link again (for folk who may have missed it like me,or just recently invested).



It gives a real sense of what Baxter is about. ....IMHO.

[buywell2] 08/9/2010 09:17

I must say I am impressed with this .... it would seem at long last that the importance of 'sales' has been given a higher priority

The investment in a better 'quality' salesforce should now start to pay dividends

What would make my day is to read CRX have landed a BIG deal .... profits from ONE big deal should fund another acquisition


Events


ISSX 9th International Meeting

Date: 4 - 8th September, 2010

Location: Istanbul, Turkey

Attending: European Business Development Team




CACO-PSB-Bay Area Meeting

Date: 17th September, 2010

Location: Foster City, CA, USA

Attending: Shawna Trudrung, West Coast Business Development




Cell-Based Assays

Date: 20 - 22nd September, 2010

Location: London, UK

Presenting: Katya Tsaioun, Chief Scientific Officer




Cyprotex Introduction to ADME Training Course

Date: 22nd September, 2010

Location: King of Prussia, PA, USA

Attending: East Coast Business Development Team




Cyprotex 6th NA Drug Discovery Workshop

Date: 23rd September, 2010

Location: King of Prussia, PA, USA

Attending: East Coast Business Development Team




11th International Conference on Alzheimer's Drug Discovery

Date: 27 - 28th September, 2010

Location: Jersey City, NJ, USA

Presenting: Katya Tsaioun, Chief Scientific Officer




Predictive In Vitro Models for Drug Development

Date: 28 - 29th September, 2010

Location: Cambridge, MA, USA

Attending: Ben Butterfield, North Amercia Business Development




Bio-Europe International 2010

Date: 15 - 17th November, 2010

Location: Munich, Germany

Attending: European Business Development Team




CACO-PBS-Bay Area Meeting

Date: 3rd December, 2010

Location: Foster City, CA, USA

Attending: Shawna Trudrung, West Coast Business Development




Genesis 2010

Date: 9th December, 2010

Location: London, UK

Attending: European Business Development Team

[moosh2] 07/9/2010 09:30

spoke too soon :/